Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER FINANCIAL RESULTS
Date:11/12/2013

of 2014.  Based on these factors, we are modifying our revenue, expense and loss guidance for 2013.  However, importantly, we are maintaining our cash balance guidance as we continue to expect Senomyx will end the year with more than $30 million in cash," Rogers noted.

For the full year 2013, Senomyx now expects:

  • Total revenues of $29 million to $30 million, of which approximately $5 million is commercial revenues
  • Total operating expenses of approximately $41 million, of which an estimated $4 million is non-cash, stock-based compensation expense
  • Net loss of $11 million to $12 million
  • Basic and diluted net loss of $0.27 to $0.29 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Financial Outlook: "When modeling our financial forecast, we compartmentalize our commercial revenue opportunities into three broad categories:  Senomyx's royalty-based collaborations with Firmenich, Nestle, and Ajinomoto; our direct sales initiative; and our PepsiCo collaboration.  Commercial revenues are modeled based on projections from our collaborators for royalty-based collaborations, plus current best estimates for sales potential from our nascent direct sales initiative.  From these three categories of commercial revenue opportunities, we expect approximately $10 million in commercial revenues in 2014, and approximately $25 million in commercial revenues in 2015.  A key assumption in our projections is that S617 will receive regulatory approval and will be commercialized in 2014.  We anticipate this growth in commercial revenues will be primarily driven by our collaboration with PepsiCo and Senomyx's direct sales.  In addition, we expect that the successful implementation of our direct sales initiative will begin to yield compelling results over the next two years and products from our Sweet Taste Program
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
    3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
    4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
    5. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
    6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
    7. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
    8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
    9. Senomyx Announces Management Update
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
    (Date:8/31/2015)... , Aug. 31, 2015  For people with ... brighten their day. The biotechnology company, located in the ... one of the best potential therapies yet for people ... entitled, " Correction of Down syndrome and Edwards syndrome ... journal DNA Research . Elixirgen plans to develop ...
    (Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have ... drug development approval process. Thus, innovator companies must understand what will be needed ... Chicago-based CMO, has been hosting multiple educational panels and seminars for experts to ...
    Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
    ... SAN JOSE, Calif., April 4, 2011 Researchers ... Institute of Bioengineering and Nanotechnology have made a ... were shown to physically detect and destroy antibiotic-resistant ... known as MRSA, while leaving healthy cells unharmed. ...
    ... TORONTO, April 4, 2011 Generex Biotechnology ... today the publication of a report comparing ... peptide vaccines designed for immunotherapy of breast ... developed by the Company,s wholly-owned subsidiary, Antigen ...
    ... CryoLife, Inc. (NYSE: CRY ), an implantable biological ... it has filed an IDE with the United ... for the purpose of obtaining Pre-Market Approval (PMA) to distribute ... or following traumatic injuries. PerClot is a ...
    Cached Biology Technology:IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment 2IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment 3IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment 4Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research 2Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research 3Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research 4CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4
    (Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
    (Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
    (Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
    Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
    ... available to health officials and businesses, a Purdue University ... of melamine in infant formula. Using infrared lasers ... of food science, was able to detect melamine in ... five minutes or less. Melamine, a synthetic chemical used ...
    ... Mittermeier, the president of Conservation International and a global ... Peterson Medal from the Harvard Museum of Natural History. ... strategist who has written more than 500 scientific and ... He has described 11 species new to science, had ...
    ... cancer researchers at The Ohio State University has ... certain proteins that may make good biomarkers in ... liquid chromatography-mass spectrometry (LC-MS) can measure variations in ... and store DNA. The technology accurately detected differences ...
    Cached Biology News:Researcher: Lasers used to detect melamine in baby formula 2Study validates means to measure possible leukemia marker 2
    ... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
    ... system designed for flexibility and routine operation. ... ion lens, true hyperbolic quadrupole and high-speed ... widest range of sample types and applications. ... as standard Agilents unique ShieldTorch System, which ...
    ... a fully automated microplate luminescence reader ... possible range of applications based on ... luciferase, -galactosidase, gene activities with luminescence ... Luminescent Immunoassays Cell-based assays (cytotoxity ...
    ... are specifically depleted of a single complement ... protein, the alternative and classical pathways are ... for the detection and quantitation of hemolytically ... used to assess complement activation in non-human ...
    Biology Products: